New User Fee Program Aims to Spur Drug Development
PDUFA III boosts manufacturer fees to expand postapproval surveillance and support new FDA review initiatives.
For full article Click Here
Journal:
Applied Clinical Trials, Aug 1, 2002
Copyright:
©Advanstar Communications, Inc. All rights reserved.